Investments
18Portfolio Exits
11About NMT Management AG - New Medical Technologies
NMT New Medical Technologies is a venture partner investing in medical and healthcare technologies and services. Its focus is to foster start-ups in Switzerland and the surrounding regions (Alpine Rim) as well as to invest globally in late stage private and promising public companies. NMT seeks investment opportunities in biopharmaceutical and medical technologies from universities and other private entities as well as spin-offs from large corporations. Furthermore, NMT attracts overseas start-ups, early- and late-stage companies to the Alpine Rim, supporting them in technology bundling and building up European operations as well as in going public. The Company was founded in 1997 by Roche, UBS and a small group of private investors. It was acquired by HbM BioVentures AG in February 2003.
Want to inform investors similar to NMT Management AG - New Medical Technologies about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
NMT Management AG - New Medical Technologies Investments
18 Investments
NMT Management AG - New Medical Technologies has made 18 investments. Their latest investment was in Sunesis Pharmaceuticals as part of their PIPE - III on September 9, 2010.
NMT Management AG - New Medical Technologies Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/9/2010 | PIPE - III | Sunesis Pharmaceuticals | $15.5M | No | Abingworth, Alta Partners, Bay City Capital, BVF Partners, Deerfield Management, Domain Associates, International Biomedicine Management Partners, International Biotechnology Trust, LODH Private Equity Partners, Mayfield, Merlin Nexus, New Enterprise Associates, Nextech Venture, NMT Management AG - New Medical Technologies, OpusPoint Partners, Skyline Ventures, SV Health Investors, Venrock, Vision Capital Advisors, and Warburg Pincus | |
1/24/2003 | Unattributed VC | Organ Recovery Systems | No | |||
1/20/2003 | Series B | Organ Recovery Systems | $14M | Yes | ||
5/22/2002 | Unattributed VC | |||||
9/7/2001 | Series D |
Date | 9/9/2010 | 1/24/2003 | 1/20/2003 | 5/22/2002 | 9/7/2001 |
|---|---|---|---|---|---|
Round | PIPE - III | Unattributed VC | Series B | Unattributed VC | Series D |
Company | Sunesis Pharmaceuticals | Organ Recovery Systems | Organ Recovery Systems | ||
Amount | $15.5M | $14M | |||
New? | No | No | Yes | ||
Co-Investors | Abingworth, Alta Partners, Bay City Capital, BVF Partners, Deerfield Management, Domain Associates, International Biomedicine Management Partners, International Biotechnology Trust, LODH Private Equity Partners, Mayfield, Merlin Nexus, New Enterprise Associates, Nextech Venture, NMT Management AG - New Medical Technologies, OpusPoint Partners, Skyline Ventures, SV Health Investors, Venrock, Vision Capital Advisors, and Warburg Pincus | ||||
Sources |
NMT Management AG - New Medical Technologies Portfolio Exits
11 Portfolio Exits
NMT Management AG - New Medical Technologies has 11 portfolio exits. Their latest portfolio exit was CardiacAssist on February 14, 2018.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
2/14/2018 | Acquired | 1 | |||
6/20/2013 | IPO | Public | 1 | ||
7/21/2011 | Acq - P2P | 1 | |||
Date | 2/14/2018 | 6/20/2013 | 7/21/2011 | ||
|---|---|---|---|---|---|
Exit | Acquired | IPO | Acq - P2P | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 1 | 1 | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.